

Please note: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval

15 May 2019

Dr Theodore Dassios
Consultant Neonatologist
Kings College London
4th Floor Golden Jubilee Wing, King's College Hospital
Denmark Hill
SE5 9RS

Dear Dr Dassios,

Study title:	Nutrition and respiratory morbidity in extremely premature infants: a retrospective five-year whole population study of neonatal networks in England.
REC reference:	19/WM/0172
Protocol number:	N/A
IRAS project ID:	259225

The Proportionate Review Sub-committee of the West Midlands - Edgbaston Research Ethics Committee reviewed the above application on 15 May 2019.

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this favourable opinion letter. The expectation is that this information will be published for all studies that receive an ethical opinion but should you wish to provide a substitute contact point, wish to make a request to defer, or require further information, please contact hra.studyregistration@nhs.net outlining the reasons for your request. Under very limited circumstances (e.g. for student research which has received an unfavourable opinion), it may be possible to grant an exemption to the publication of the study.

Ethical opinion

On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System, www.hra.nhs.uk or at <http://www.rdforum.nhs.uk>.

Where a NHS organisation's role in the study is limited to identifying and referring potential participants to research sites ("participant identification centre"), guidance should be sought from the R&D office on the information it requires to give permission for this activity.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations.

Registration of Clinical Trials

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database. This should be before the first participant is recruited but no later than 6 weeks after recruitment of the first participant.

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to request a deferral for study registration within the required timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will be registered, however, in exceptional circumstances non registration may be permissible with prior agreement from the HRA. Guidance on where to register is provided on the HRA website.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

Ethical review of research sites

The favourable opinion applies to all NHS sites taking part in the study, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see “Conditions of the favourable opinion”).

Approved documents

The documents reviewed and approved were:

<i>Document</i>	<i>Version</i>	<i>Date</i>
IRAS Application Form [IRAS_Form_26042019]		26 April 2019
Letter from sponsor [Indemnity/Insurance]	1	09 July 2018
Other [Validation query]		08 May 2019
Research protocol or project proposal [Protocol]	v1.0	15 January 2019
Summary CV for Chief Investigator (CI) [CI summary CV]	1	01 January 2019
Summary CV for student [Student CV]	1	30 November 2018

Membership of the Proportionate Review Sub-Committee

The members of the Sub-Committee who took part in the review are listed on the attached sheet.

Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

After ethical review

Reporting requirements

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website:

<http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>

HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at:

<https://www.hra.nhs.uk/planning-and-improving-research/learning/>

With the Committee's best wishes for the success of this project.

19/WM/0172	Please quote this number on all correspondence
-------------------	---

Yours sincerely,

P.P. 

Mr Paul Hamilton
Chair

Email: NRESCommittee.WestMidlands-Edgbaston@nhs.net

Enclosures: List of names and professions of members who took part in the review

"After ethical review – guidance for researchers"

Copy to: Professor Reza Rezavi

Lead Nation

England: HRA.Approval@nhs.net

West Midlands - Edgbaston Research Ethics Committee

Attendance at PRS Sub-Committee of the REC meeting on 15 May 2019

Committee Members:

<i>Name</i>	<i>Profession</i>	<i>Present</i>	<i>Notes</i>
Dr Oladipo Babalola	Relief Pharmacy Manager	Yes	
Dr Hora Ejtehad	Senior Academic Lecturer	Yes	
Mr Paul Hamilton	Parish Administrator	Yes	

Also in attendance:

<i>Name</i>	<i>Position (or reason for attending)</i>
Ms Kate Loven	Approvals Administrator